☰

Ming J. Poi, Ph.D. - Publications

Affiliations: 
2002 Ohio State University, Columbus, Columbus, OH 
Area:
Biochemistry, Molecular Biology
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Li J, Vangundy Z, Poi M. Cisplatin Induced the Expression of () Oncogene in Human Oral Squamous Cancer Cell Lines. Anticancer Research. 40: 67-73. PMID 31892553 DOI: 10.21873/Anticanres.13926  0.3
2019 Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, Phelps MA, Hofmeister CC, Poi MJ. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. Molecular Carcinogenesis. PMID 31544312 DOI: 10.1002/Mc.23121  0.337
2019 Poi MJ, Li J, Johnson JA, Cho YK, Sborov DW, Phelps MA, Hofmeister CC. A Single Nucleotide Polymorphism in Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research. 39: 67-72. PMID 30591441 DOI: 10.21873/Anticanres.13080  0.348
2017 Poi MJ, Knobloch TJ, Li J. Deletion of RD(INK4/ARF) enhancer: A novel mutation to "inactivate" the INK4-ARF locus. Dna Repair. 57: 50-55. PMID 28688373 DOI: 10.1016/J.Dnarep.2017.06.027  0.329
2017 Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, et al. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia & Lymphoma. 1-9. PMID 28270022 DOI: 10.1080/10428194.2017.1298751  0.366
2017 Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, et al. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clinical Pharmacology and Therapeutics. PMID 28160288 DOI: 10.1002/Cpt.644  0.37
2017 Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Molecular Carcinogenesis. PMID 28150872 DOI: 10.1002/Mc.22626  0.392
2016 Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen CS, Kulp SK. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie. PMID 27555377 DOI: 10.1016/J.Etp.2016.08.001  0.341
2016 Jamieson GC, Fox JA, Poi M, Strickland SA. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs. PMID 27484675 DOI: 10.1007/S40265-016-0614-Z  0.367
2016 Awan FT, Jones JA, Maddocks K, Poi M, Grever MR, Johnson A, Byrd JC, Andritsos LA. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. Annals of Hematology. PMID 27118540 DOI: 10.1007/S00277-016-2683-1  0.383
2016 Valencia H, Newton HB, Hade E, Sborov DW, Cavaliere R, Poi M, Phelps M, Wang J, Coss CC, Khountham S, Monk P, Olencki T, Shapiro CL, Piekarz R, Hofmeister CC, et al. A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors. Journal of Clinical Oncology. 34: 2558-2558. DOI: 10.1200/Jco.2016.34.15_Suppl.2558  0.388
2016 Wesolowski R, Lustberg MB, Mrozek E, Layman R, Reinbolt R, Poi M, Osman N, Lively A, Stephens J, Grever M, Ramaswamy B. Abstract CT033: Phase 1b study of heat shock protein 90 inhibitor onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct033  0.344
2015 Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. 169: 701-10. PMID 25847298 DOI: 10.1111/Bjh.13354  0.348
2015 Poi MJ, Knobloch TJ, Sears MT, Warner BM, Uhrig LK, Weghorst CM, Li J. Alterations in RD(INK4/ARF) -mediated en bloc regulation of the INK4-ARF locus in human squamous cell carcinoma of the head and neck. Molecular Carcinogenesis. 54: 532-42. PMID 24302590 DOI: 10.1002/Mc.22119  0.339
2014 Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leukemia Research. 38: 1025-9. PMID 25082342 DOI: 10.1016/J.Leukres.2014.05.011  0.358
2014 Poi MJ, Drosdeck J, Frankel WL, Muscarella P, Li J. Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. Pancreas. 43: 1009-13. PMID 25003221 DOI: 10.1097/Mpa.0000000000000165  0.331
2014 Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, et al. Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. Clinical Pharmacology and Therapeutics. 96: 182-91. PMID 24781527 DOI: 10.1038/Clpt.2014.93  0.334
2014 Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JC. A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology. 73: 249-57. PMID 24241210 DOI: 10.1007/S00280-013-2347-Y  0.319
2014 Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. American Journal of Hematology. 89: 19-24. PMID 23959599 DOI: 10.1002/Ajh.23568  0.378
2014 Li J, Knobloch TJ, Poi MJ, Zhang Z, Davis AT, Muscarella P, Weghorst CM. Genetic alterations of RD(INK4/ARF) enhancer in human cancer cells. Molecular Carcinogenesis. 53: 211-8. PMID 23065809 DOI: 10.1002/Mc.21965  0.359
2014 Sborov DW, Lamprecht M, Benson D, Tackett K, Efebera YA, Ashley RE, Devine SM, Poi M, Phelps MA, Hofmeister CC. 2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial Blood. 124: 3960-3960. DOI: 10.1182/Blood.V124.21.3960.3960  0.373
2014 Cho YK, Li J, Sborov DW, Wang J, Gao Y, Lamprecht M, Poi M, Phelps MA, Hofmeister CC. Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma Blood. 124: 1086-1086. DOI: 10.1182/Blood.V124.21.1086.1086  0.356
2013 Poi MJ, Knobloch TJ, Yuan C, Tsai MD, Weghorst CM, Li J. Evidence that P12, a specific variant of P16(INK4A), plays a suppressive role in human pancreatic carcinogenesis. Biochemical and Biophysical Research Communications. 436: 217-22. PMID 23727582 DOI: 10.1016/J.Bbrc.2013.05.078  0.355
2013 Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clinical Pharmacokinetics. 52: 705-12. PMID 23588536 DOI: 10.1007/S40262-013-0064-7  0.316
2013 Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1269-80. PMID 23300276 DOI: 10.1158/1078-0432.Ccr-12-1092  0.356
2011 Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 50: 5566-82. PMID 21619050 DOI: 10.1021/Bi200642E  0.341
2010 Christian B, Alinari L, Jones JA, Benson DM, Flynn JM, Porcu P, Lustberg ME, Phelps M, Poi M, Chung D, Quinion C, Byrd JC, Wegener W, Goldenberg DM, Baiocchi RA, et al. Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma, Blood. 116: 2788-2788. DOI: 10.1182/Blood.V116.21.2788.2788  0.338
2004 Li J, Weghorst CM, Tsutsumi M, Poi MJ, Knobloch TJ, Casto BC, Melvin WS, Tsai MD, Muscarella P. Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis. 25: 263-8. PMID 14604895 DOI: 10.1093/Carcin/Bgh007  0.34
2001 Poi MJ, Yen T, Li J, Song H, Lang JC, Schuller DE, Pearl DK, Casto BC, Tsai MD, Weghorst CM. Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck. Molecular Carcinogenesis. 30: 26-36. PMID 11255261 DOI: 10.1002/1098-2744(200101)30:1<26::Aid-Mc1010>3.0.Co;2-E  0.346
2000 Li J, Poi MJ, Qin D, Selby TL, Byeon IJ, Tsai MD. Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4. Biochemistry. 39: 649-57. PMID 10651629 DOI: 10.1021/Bi991281U  0.314
Show low-probability matches.